<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180163</url>
  </required_header>
  <id_info>
    <org_study_id>SHP643-302</org_study_id>
    <nct_id>NCT04180163</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)</brief_title>
  <official_title>A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 3, open-label, multi center study is to evaluate the safety and
      efficacy of lanadelumab in Japanese participants with HAE Type I or II.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Study will consist of 52-week treatment period and a 4-week follow-up period. 52-week
      treatment period comprises of a 26-week treatment period A (Day 0 to Day 182) and a 26-week
      treatment period B (Day 183 to Day 364). Participants who complete treatment period A will
      immediately continue into treatment period B.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving Attack-Free Status for the Efficacy Evaluation Period of Day 0 Through Day 182</measure>
    <time_frame>Day 0 through Day 182</time_frame>
    <description>A participant will be considered as attack free during an efficacy evaluation period if the participant has no investigator-confirmed HAE attacks during that efficacy evaluation period. A HAE attack is defined as the symptoms or signs consistent with an attack in at least 1 of the following locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). Number of participants achieving attack-free status for the efficacy evaluation period of day 0 through day 182 will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods</measure>
    <time_frame>Day 0 through Day 182, Day 0 through Day 364, Day 70 through Day 182, Day 70 through Day 364</time_frame>
    <description>Efficacy evaluation period will consist of four periods: Day 0 (after study drug administration) through Day 182 (the end of Treatment Period A), Day 0 (after study drug administration) through Day 364 (the end of Treatment Period B), presumed steady-state period from Day 70 through Day 182, presumed steady-state period from Day 70 through Day 364. Number of investigator-confirmed HAE attacks during each of the efficacy evaluation periods will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Investigator-Confirmed Hereditary Angioedema (HAE) Attacks Requiring Acute Treatment During Each of the Efficacy Evaluation Periods</measure>
    <time_frame>Day 0 through Day 182, Day 0 through Day 364, Day 70 through Day 182, Day 70 through Day 364</time_frame>
    <description>Number of investigator-confirmed HAE attacks requiring acute treatment during each of the efficacy evaluation periods will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Moderate or Severe Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods</measure>
    <time_frame>Day 0 through Day 182, Day 0 through Day 364, Day 70 through Day 182, Day 70 through Day 364</time_frame>
    <description>Severe attack is defined as grade 3 (some assistance usually required, medical intervention/therapy required, hospitalizations possible), moderate attack is defined as grade 2 (some assistance may be needed, no or minimal medical intervention/therapy required). Number of investigator-confirmed moderate or severe HAE attacks during the each of efficacy evaluation periods will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Maximum Attack Severity During Each of the Efficacy Evaluation Periods</measure>
    <time_frame>Day 0 through Day 182, Day 0 through Day 364, Day 70 through Day 182, Day 70 through Day 364</time_frame>
    <description>Number of participants with maximum attack severity during each of the efficacy evaluation periods will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of High-Morbidity Investigator-Confirmed Hereditary Angioedema (HAE) Attacks During Each of the Efficacy Evaluation Periods</measure>
    <time_frame>Day 0 through Day 182, Day 0 through Day 364, Day 70 through Day 182, Day 70 through Day 364</time_frame>
    <description>A high morbidity HAE attack is defined as any attack that has at least 1 of the following characteristics: severe, results in hospitalization (except hospitalization for observation less than (&lt;) 24 hours), hemodynamically significant (systolic blood pressure less than &lt; 90, requires intravenous (IV) hydration, or associated with syncope or near syncope) or laryngeal. Number of high-morbidity investigator-confirmed HAE attacks during each of the efficacy evaluation periods will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Hereditary Angioedema (HAE) Attack After Day 0 for the Efficacy Evaluation Period of Day 0 Through Day 182</measure>
    <time_frame>Day 0 through Day 182</time_frame>
    <description>The time to the first HAE attack (days) after Day 0 for the efficacy evaluation period of Day 0 through Day 182 will be calculated from the date and time of the first dose of lanadelumab for the efficacy evaluation period (Day 0 through Day 182) to the date and time of the first in HAE attack after the first open-label dose for the efficacy evaluation period of Day 0 through Day 182.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Hereditary Angioedema (HAE) Attack After Day 0 for the Efficacy Evaluation Period of Day 70 Through Day 182</measure>
    <time_frame>Day 70 through Day 182</time_frame>
    <description>The time to the first HAE attack (days) after Day 0 for the efficacy evaluation period of Day 70 through Day 182 will be calculated from the date and time of the first dose of lanadelumab for the efficacy evaluation period (Day 70 through Day 182) to the date and time of the first in HAE attack after the first open-label dose for the efficacy evaluation period of Day 70 through Day 182.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving at Least 50 %, 70% and 90% Reduction in the Investigator-Confirmed Normalized Number of Attacks (NNA) per 4 Weeks Relative to the Run-in Period Normalized Number of Attacks (NNA) for Each of Efficacy Evaluation Periods</measure>
    <time_frame>Day 0 through Day 182, Day 0 through Day 364, Day 70 through Day 182, Day 70 through Day 364</time_frame>
    <description>Run in period will be 4 weeks and may be extended up to 8 weeks to determine their baseline attack rate. The normalized number of investigator-confirmed HAE attacks (NNA) during each efficacy evaluation period will be expressed as a monthly (28 days) HAE attack rate. Number of participants achieving at least 50 percent (%), 70% and 90% reduction in the investigator-confirmed NNA per 4 weeks relative to the run-in period normalized NNA for each of the efficacy evaluation period will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Normalized Number of Attacks (NNA) Less than (&lt;) 1.0 per 4 weeks, Less than (&lt;)0.75 per 4 weeks, Less than (&lt;) 0.50 per 4 weeks, and Less than (&lt;) 0.25 per 4 weeks for Each of the Efficacy Evaluation Periods</measure>
    <time_frame>Day 0 through Day 182, Day 0 through Day 364, Day 70 through Day 182, Day 70 through Day 364</time_frame>
    <description>The normalized number of investigator-confirmed HAE attacks (NNA) during each efficacy evaluation period will be expressed as a monthly (28 days) HAE attack rate. Number of participants achieving NNA &lt;1.0 per 4 weeks, &lt;0.75 per 4 weeks, &lt;0.50 per 4 weeks, and &lt;0.25 per 4 weeks for each of the efficacy evaluation periods will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Attack-Free Status for the Efficacy Evaluation Period of Day 0 Through Day 364, Day 70 Through Day 182, and Day 70 Through Day 364</measure>
    <time_frame>Day 0 through Day 364, Day 70 through Day 182, and Day 70 through Day 364</time_frame>
    <description>A participant will be considered as attack free during an efficacy evaluation period if the participant has no investigator-confirmed HAE attacks during that efficacy evaluation period. A HAE attack is defined as the symptoms or signs consistent with an attack in at least 1 of the following locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). Number of participants achieving attack-free status for the efficacy evaluation period of day 0 through day 364 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Attack Free Days During Each of the Efficacy Evaluation Periods</measure>
    <time_frame>Day 0 through Day 182, Day 0 through Day 364, Day 70 through Day 182, Day 70 through Day 364</time_frame>
    <description>An attack-free day is defined as a calendar day with no investigator-confirmed HAE attack. HAE attack free days will be calculated by counting the number of days in the efficacy evaluation period without an HAE attack and dividing by the number of days the participant contributed to the efficacy evaluation period. Percentage of attack free days during each of the efficacy evaluation periods will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From start of the study up to follow up (Day 392)</time_frame>
    <description>A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with an investigational product (IP) or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the IP or medicinal product. A SAE is any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, congenital abnormality/birth defect, an important medical event. AESI will include hypersensitivity reactions, events of disordered coagulation such as bleeding AESI, hypercoagulable AESI. Number of participants with TEAEs including AESI and SAE will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Lanadelumab</measure>
    <time_frame>Day 0, 56, 98, 140, 182, 266, 350, 364 and 392</time_frame>
    <description>Plasma Concentrations of Lanadelumab will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioedema Quality of life (AE-QoL) Questionnaire</measure>
    <time_frame>Day 0, 28, 56, 98, 126, 154, 182, 266, 364 and 392</time_frame>
    <description>The AE-QoL questionnaire is a self-administered validated instrument to assess health related (HR)QoL among participants with recurrent angioedema (including HAE). The AE-QoL consists of 17 disease-specific quality-of-life items, to produce a total AE-QoL score and 4 domain scores (functioning, fatigue/mood, fear/shame, and nutrition) and each of the 17 items has a five-point response scale ranging from 1 (Never) to 5 (Very Often).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Kallikrein (pKal) Activity</measure>
    <time_frame>Day 0, 56, 98, 140, 182, 266, 350, 364 and 392</time_frame>
    <description>pKal activity will be measured by biomarker cleaved high molecular weight kininogen (cHMWK ) level to assess pharmacodynamics (PD) of lanadelumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-drug Antibody (ADA) in Plasma</measure>
    <time_frame>Day 0, 56, 98, 140, 182, 266, 350, 364 and 392</time_frame>
    <description>Number of participants with positive ADA in plasma will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Hereditary Angioedema (HAE)</condition>
  <arm_group>
    <arm_group_label>Lanadelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 300 milligram (mg) lanadelumab solution once every 2 weeks (q2w) for 26 weeks (treatment period A), followed by treatment period B during which participants may remain on treatment period A regimen or will receive 300 mg lanadelumab solution once every 4 weeks (q4w) for 26 weeks if well tolerated with overall treatment period of 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanadelumab</intervention_name>
    <description>Participants receive 300 mg of lanadelumab solution q2w (treatment period A) for 26 weeks and q2w or q4w (treatment period B) for 26 weeks, for overall 52 weeks of treatment period.</description>
    <arm_group_label>Lanadelumab</arm_group_label>
    <other_name>DX-2930</other_name>
    <other_name>TAK-743</other_name>
    <other_name>SHP643</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be of Japanese descent, defined as born in Japan and having Japanese parents and
             Japanese maternal and paternal grandparents.

          -  The participant is male or female and greater than or equal to (&gt; =) 12 years of age
             at the time of informed consent.

          -  Documented diagnosis of HAE (Type I or II) based upon all of the following:

               1. Documented clinical history consistent with HAE (subcutaneous or mucosal,
                  nonpruritic swelling episodes without accompanying urticaria).

               2. Diagnostic testing results obtained during screening that confirm HAE Type I or
                  II: C1 inhibitor (C1-INH) functional level less than (&lt;)40 percent (%) of the
                  normal level. Participants with functional C1-INH level 40-50% of the normal
                  level may be enrolled if they also have a C4 level below the normal range. With
                  prior sponsor approval, participants may be retested during the run-in period if
                  results are in congruent with clinical history or believed by the investigator to
                  be confounded by recent C1 inhibitor use.

               3. At least one of the following: age at reported onset of first angioedema symptoms
                  less than or equal to (&lt; or =) 30 years, a family history consistent with HAE
                  Type I or II, or C1q within normal range.

          -  Attack rate: Participants must experience at least 1 investigator-confirmed HAE attack
             per 4 weeks during the run-in period to enter the lanadelumab treatment period.

          -  The participant (or the participants parent/legal authorized representative, if
             applicable) has provided written informed consent approved by the Institutional Review
             Board/Independent Ethics Committee (IRB/IEC).

          -  If the participant is an adult, be informed of the nature of the study and provide
             written informed consent before any study-specific procedures are performed or if the
             participant is a minor (ie, below the age of majority), have a parent/legally
             authorized representative who is informed of the nature of the study provide written
             informed consent (ie, permission) for the minor to participate in the study before any
             study-specific procedures are performed. Assent will be obtained from minor
             participants.

          -  Males, or non pregnant, non lactating females who are fertile and sexually active and
             who agree to be abstinent or agree to comply with the applicable contraceptive
             requirements of this protocol for the duration of the study, or females of non child
             bearing potential, defined as surgically sterile (status post hysterectomy, bilateral
             oophorectomy, or bilateral tubal ligation) or postmenopausal for at least 12 months.

          -  Agree to adhere to the protocol-defined schedule of assessments and procedures.

        Exclusion Criteria:

          -  Concomitant diagnosis of another form of chronic, recurrent angioedema, such as
             acquired angioedema (AAE), HAE with normal C1-INH (also known as HAE Type 3),
             idiopathic angioedema, or recurrent angioedema associated with urticaria.

          -  Participation in a prior lanadelumab study.

          -  Dosing with investigational drug or exposure to an investigational device within 4
             weeks prior to entering to screening.

          -  Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing
             medications with systematic absorption (such as oral contraceptives or hormonal
             replacement therapy) within 4 weeks prior to screening.

          -  Exposure to androgens (eg, danazol, methyltestosterone, testosterone) within 2 weeks
             prior to entering the run-in period.

          -  Use of long-term prophylactic therapy for HAE (C1-INH, attenuated androgens, or
             anti-fibrinolytics) within 2 weeks prior to entering the run in period.

          -  Use of short-term prophylaxis for HAE 7 days prior to entering the run-in period.
             Short-term prophylaxis is defined as C1-INH, attenuated androgens, or
             anti-fibrinolytics used to avoid angioedema complications from medically indicated
             procedures.

          -  Any of the following liver function abnormalities: alanine aminotransferase (ALT)
             greater than (&gt;) 3x upper limit of normal, or aspartate aminotransferase (AST) &gt;3x
             upper limit of normal or bilirubin &gt;2x upper limit of normal (unless the bilirubin is
             a result of Gilbert's syndrome).

          -  Pregnancy or breast feeding.

          -  Participant has any condition that in the opinion of the investigator or sponsor, may
             compromise their safety or compliance, preclude successful conduct of the study, or
             interfere with interpretation of the results (eg, history of substance abuse, or
             dependence, significant preexisting illnesses or major comorbidity the investigator
             considers may confound the interpretation of the study results).

          -  Participant has a known hypersensitivity to the IP or its components.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toyohashi Municipal Hospital</name>
      <address>
        <city>Toyohashi-shi</city>
        <state>Aichi-Ken</state>
        <zip>441-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Hideko Yamamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asahi General Hospital</name>
      <address>
        <city>Asahi-shi</city>
        <state>Chiba-Ken</state>
        <zip>289-2511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Shinichiro Kagami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ogaki Municipal Hospital</name>
      <address>
        <city>Ogaki-shi</city>
        <state>Gifu-Ken</state>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Hajime Takagi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima-Ken</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Kazumasa Iwamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tomakomai City Hospital</name>
      <address>
        <city>Tomakomai-shi</city>
        <state>Hokkaido</state>
        <zip>053-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Tomoe Kobayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo-Ken</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Atsushi Fukunaga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara-shi</city>
        <state>Kanagawa-Ken</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Tomotaka Mabuchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa-Ken</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Naoko Inomata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto-Fu</state>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Kohei Yamashita</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka-Fu</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Yukinobu Nakagawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saiyu Soka Hospital</name>
      <address>
        <city>Soka-shi</city>
        <state>Saitama-Ken</state>
        <zip>340-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Isao Osawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital</name>
      <address>
        <city>Izumo-shi</city>
        <state>Shimane-Ken</state>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Eishin Morita</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

